Partnership Institut Curie names Intel lead partner to implement high performance computing and artificial intelligence in accelerating genome sequencing and interpretation for oncology 05/22/2018
DNA Thearpeutics was acquired in 2016 by ONXEO. First-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment www.onxeo.com Innovation Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor 04/24/2018
DNA Thearpeutics was acquired in 2016 by ONXEO. First-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment www.onxeo.com
Developing microfluidic solutions to make microfluidics easy https://www.fluigent.com Partnership The HoliFAB project, led by Fluidgent, a spin-off from Institut Curie, wins €7.1 million in funding. 04/18/2018
Partnership PEP-Therapy, Institut Curie and Gustave Roussy obtain 2,9 M€ to develop a novel peptide in oncology 04/16/2018
Partnership Institut Curie and Mirada Medical sign a collaboration agreement for the clinical use of DLCExpert™, Mirada’s artificial intelligence (AI)-based autocontouring software for radiation therapy 04/11/2018
Partnership Institut Curie unique french clincal center of a massive Philips Research-led big data consortium funded by EU to improve healthcare outcomes 03/29/2018
Partnership Institut Curie and Freenome announce a strategic collaboration in cell-free DNA analysis using machine learning technology 03/28/2018
Partnership Institut Curie, CNRS, AP-HP and ElsaLys Biotech sign an exclusive licence agreement to develop an anti-TYRO3 therapeutic antibody 02/20/2018